Top Markets
#1 DogBull DogBull +107.56%
#2 Siacoin Siacoin +69.48%
#3 MarsCoin MarsCoin +53.56%
#4 The Bitcoin Bull The Bitcoin Bull +32.60%
#5 ADO Protocol ADO Protocol +28.56%
#6 UnifAI Network UnifAI Network +12.19%
#7 Akedo Akedo +11.96%
#8 Cash Cat Cash Cat +11.02%
#9 Ontology Gas Ontology Gas +10.90%
#10 Apertum Apertum +10.15%
Coin of the day
DogBull DogBull
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
IX Biopharma Ltd. IX Biopharma Ltd.

IX Biopharma Ltd.

42C
Classificação em ações #14765
iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical enterprise... iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical enterprise headquartered in Singapore since its inception in 2004, focuses on the research, development, manufacturing, and commercialization of therapeutic solutions. The company targets acute and breakthrough pain, alongside various other health conditions, serving markets in Singapore, the United States, China, and Australia through its Specialty Pharmaceutical and Nutraceutical divisions. Its commercial offerings include Wafesil and Silcap, both indicated for male erectile dysfunction. Additionally, the company markets Xativa, a sublingual cannabidiol wafer, and Hypera, a sublingual tetrahydrocannabinol wafer, which address chronic pain, anxiety, and insomnia. iX Biopharma boasts an extensive product pipeline. Wafermine, a racemic ketamine sublingual wafer designed for complex regional pain syndrome and psychiatric conditions like depression, has successfully advanced through Phase 2 clinical trials. Other investigational candidates that have completed Phase 1 trials include iXB 120 for acute agitation, IXB-214 for complex regional pain syndrome, and IXB-314 for treatment-resistant depression. Furthermore, BnoX is currently undergoing Phase 1 evaluation for moderate to severe pain. In earlier development stages, iXB 401, a sublingual semaglutide wafer, is in pre-clinical development for Type 2 Diabetes and obesity. The pipeline also encompasses SL-NAD+, a sublingual NAD+ wafer engineered to boost the body's NAD+ levels, energy, and alertness; a distinct NAD+ product targeting sarcopenia; iXB 321, an influenza vaccine; iXB 322, a novel low-dose interferon sublingual wafer for respiratory viral prophylaxis; and LumeniX, a sublingual glutathione wafer offering benefits for skin brightening and immunity.
Preço da ação
$0.36004668
Valor de mercado
$393.64M
Variação (1 dia)
7.06%
Variação (1 ano)
2,211.24%
País
SG
Negociar IX Biopharma Ltd. (42C)

Categoria

Healthcare
Histórico de preços das ações de IX Biopharma Ltd. (42C)
Preço de fecho mais alto: $0.36 em 2026-09-01

Preço de fecho mais baixo: $0.33 em 2015-07-01
Histórico de preços das ações da IX Biopharma Ltd. de 2015 a 2026
Desempenho anual do preço das ações
Ano Desempenho
2026 (TTM) 106.54%
2025 446.22%
2024 -48.98%
2023 -64.13%
2022 -39.03%
2021 -15.40%
2020 14.66%
2019 26.68%
2018 -16.98%
2017 -23.25%
2016 -34.06%
2015 0.00%
Preço das ações de empresas similares ou concorrentes
Empresa Preço da ação Variação 1a% País
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
 $171.67 -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
 $167.72 31.75%
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
 $38.30 26.13%
JP
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
 $21.25 19.61%
IN
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
 $214.79 22.87%
CH